Certainty in an Uncertain Market?
Antigenics Success in Russia, Also a 'Personalized' Win
By Tiffany Turner
Monday, April 21, 2008
Personalized medicine became more than a buzzword two weeks ago. When the Russian Ministry of Public Health approved Oncophage, Antigenics Inc.'s cancer vaccine, it marked the first such approval for a personalized vaccine from a major country, and it shines new light on that system of disease treatment and management. (BioWorld Financial Watch)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.